Allogene Therapeutics, Inc. (ALLO) Financials
ALLO Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 642.8 million | 130.6 million |
2023-09-30 | 712.3 million | 129.2 million |
2023-06-30 | 771.0 million | 148.1 million |
2023-03-31 | 746.9 million | 154.6 million |
ALLO Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -53.9 million | 15.2 million |
2023-09-30 | -55.5 million | 15.4 million |
2023-06-30 | -62.1 million | 16.6 million |
2023-03-31 | -67.7 million | 18.8 million |
ALLO Net Income
No data available :(
ALLO Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 448.7 million | - | 95.1 million |
2023-09-30 | 465.5 million | - | 90.1 million |
2023-06-30 | 492.0 million | - | 91.8 million |
2023-03-31 | 514.0 million | - | 99.7 million |
ALLO Shares Outstanding
ALLO Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 181000 | 54.7 million | 17.2 million | - |
2023-09-30 | 12000 | 46.0 million | 17.0 million | - |
2023-06-30 | 288000 | 62.0 million | 18.5 million | - |
2023-03-31 | 1.0 million | 80.2 million | 18.9 million | - |
ALLO Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 21000 | - |
2023-09-30 | 43000 | 3.6 million |
2023-06-30 | 44000 | 3.8 million |
2023-03-31 | 52000 | 3.7 million |
ALLO
Price: $3
52 week price:
Earnings Per Share: -2.09 USD
P/E Ratio: -2.10
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 358933
Market Capitalization: 674.7 million